Lv1
60 积分 2022-07-27 加入
Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
13小时前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
14小时前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
14小时前
已完结
Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases
24天前
已完结
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies
30天前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
1个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
1个月前
已关闭
Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020
1个月前
已完结
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer
1个月前
已完结
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
